Wordt geladen...
Empagliflozin protects against atherosclerosis progression by modulating lipid profiles and sympathetic activity
BACKGROUND: Several large clinical trials have confirmed the cardioprotective role of sodium-glucose cotransporter 2 inhibitors (SGLT2i) in patients with type 2 diabetes. However, whether empagliflozin, as an SGLT2i, could alleviate atherosclerosis progression in non-diabetic states remain unknown....
Bewaard in:
| Gepubliceerd in: | Lipids Health Dis |
|---|---|
| Hoofdauteurs: | , , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
BioMed Central
2021
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7802233/ https://ncbi.nlm.nih.gov/pubmed/33436015 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12944-021-01430-y |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|